Crystal diseases, metabolic bone diseases and bone diseases other than osteoporosis
3 Rheumatology, Lariboisière Hospital, Paris; 4 Rheumatology, Lapeyronie Hospital, Montpellier, France Background: Ultrasonography (US) has demonstrated its ability to detect urate deposition in gouty patients. Some US features have been suggested to be specific such as tophus and the double contour (DC) sign. In contrast to the usefulness of US for diagnosis, data are lacking on its role in follow-up of gout deposition after initiation of urate-lowering therapy (ULT). Objectives: We aimed to determine the ability of US to show disappearance of urate deposits in gouty patients requiring ULT.
Methods: We performed a 6-month multicentre prospective study. To be included in the study, patients needed to have: i) a proven gout (identification of monosodic urate crystal in synovial fluid analysis or tophus aspiration), ii) presence of US features of gout (tophus and/or DC sign) at knee and/or first metatarsophalangeal joints (MTP1s). Serum uric-acid (SUA) level was assessed at baseline, M3 and M6. US evaluations were performed at baseline, M3 and M6 after starting ULT, by one local rheumatologist, blinded to SUA levels and clinical data. The primary outcome was the decrease (absolute value and percentage of decrease) of US tophus after 6 months of ULT, according to the final SUA levels. The secondary outcome was the mean percentage of joint sites with DC sign disappearance. Three stages of SUA levels were defined (high SUA levels: >360 μmol/l, low SUA: 300 -360 μmol/l, very low SUA: <300 μmol/l. Results: A total of 79 gouty patients (mean ± SD age 61.8±14 years, 91% of males) were included. The mean disease duration was 6.3±6.1 years. Tophi were found at clinical exam in 29% of patients. Baseline SUA levels were 530±97 μmol/l. At least one US tophus and DC sign were found in 74 (93.7%) and 68 (86.1%) of patients, respectively. Allopurinol and febuxostat was started in 26 (33%) and 53 (67%) patients, respectively. A total of 67 patients were completers at 6 months. Among those M6 completers, 39 and 18 patients achieved a very low and low SUA levels, respectively. The 10 remaining patients maintained high SUA levels. Comparison of US features of gout modifications between the 3 groups of final SUA levels revealed a higher decrease of US tophus size and higher proportion of DC sign dissolution among patients with lowest SUA levels ( Background: A higher risk of urolithiasis has been reported in gout patients. However, whether urate-lowering treatments, including both xanthine oxidase inhibotors and uricosuric agents, are beneficial to reduce the risk or urolithiasis in gout patients has not been examined. Objectives: To investigate the independent associations between urate-lowering treatment (ULT) and the risk of urolithiasis in incident gout patients. Methods: We conducted a nested case-control study based on the Taiwan National Health Insurance Research Database (NHIRD), which was used to identify 473,858 newly diagnosis gout patients during the period from January 1, 2000 through December 31, 2004. All these patients were followed until December 31, 2013. We considered patients who first diagnose incident urolithiasis after the date of entry cohort (gout onset) as cases and the diagnostic date was defined as index date. Each case was matched up to five eligible controls whose follow-up period included the case's index date by sex, birth of year and gout diagnosis year. And the index date of case was assigned to the matched controls. Odds ratios (ORs) and 95% confidence interval (CI) of urolithiasis associated with cumulative defined daily dose (cDDD) of xanthine oxidase inhibitor and uricosuric agents were main ourcome measures. Results: Gout patients with incident urolithiasis (n=32,654) occurring after the initial diagnosis of gout aged 20-79 were age-and sex-matched 1:5 to 163,270 gout patients without urolithiasis. After adjusting for age, sex, urbanization status, income, occupation, and pertinent drugs and comorbidities, the OR of urolithiasis associated with use of ULT among gout patients were 1.04 (95% CI 1.00 to 1. 
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Background: Patients with gout are usually seen in primary care. There are numerous reports regarding severity of gout in cohort studies and patients seen in more specialized care, less is known about the spectrum of severity of the disease in primary care. Objectives: To describe the pattern of self-reported disease severity of gout and predictors thereof in a primary care setting. Methods: All patients above 18 with an ICD10-diagnosis of gout at a health care visit in primary care (Jan 2015 through Aug 2016) were identified from primary care within the Western Sweden Health Care Region (WSHCR). 941 patients were identified and included in the study. They were sent a questionnaire with questions regarding comorbidities, demographics, gout characteristics and Health Assessment questionnaire (HAQ) reflecting disability. Self-reported disease severity was assessed by a three-level Likert scale (mild, moderate, severe). Possibly associated factors were analyzed by bivariate logistic regression (binary outcome: mild vs. moderate/severe) models and factors that were statistically significant were further analyzed by multivariate analysis. Results: The response rate was 54%. Response rates were significantly lower in women overall and in men under the age of 50. Covariates that were significantly associated with more severe self-reported severity of gout in the bivariate logistic regression models (Table 1) were: female sex, hyperlipidemia, higher number of previous attacks, attack during last month, HAQ. In the multivariate analysis objective measures of gout severity such as more than ten previous attacks and attack during last month were strongly associated with the patients grading of severity, in addition to presence of hyperlipidemia (Table 1) . 
